P17.64 ANGIOGENIC AND PROCOAGULANT FACTORS IN PLASMA OF BRAIN TUMOUR PATIENTS TREATED WITH BEVACIZUMAB

Por Pace, A., Antenucci, A., Mandoj, C., Villani, V., Carapella, C.M., Fabi, A., Conti, L.
Publicado em 2014

P16.06 EARLY PERFUSION CHANGES IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMAS TREATED WITH BEVACIZUMAB: PRELIMINARY EVALUATION BY THE PARAMETRIC RESPONSE MAP DERIVED FROM DYNAMIC CO...

Por Vidiri, A., Marzi, S., Piludu, F., Villani, V., Antenucci, A., Terrenato, I., Fabi, A., Pace, A., Carapella, C.M.
Publicado em 2014

P17.93 THIRD LINE CHEMOTHERAPY IN HIGH GRADE GLIOMAS: THERE IS A BENEFIT?

Por Villani, V., Fabi, A., Terrenato, I., Telera, S., Marucci, L., Carosi, M., Vidiri, A., Carapella, C.M., Pace, A.
Publicado em 2014

P18.06 ZONISAMIDE AS ADD-ON ANTIEPILEPTIC DRUG IN PATIENTS WITH BRAIN TUMOR-RELATED EPILEPSY: PRELIMINARY DATA OF A PILOT STUDY

Por Maschio, M., Dispenza, S., Dinapoli, L., Giannarelli, D., Fabi, A., Pompili, A., Carapella, C.M., Vidiri, A., Pace, A., Cantelmi, T.
Publicado em 2014

P16.25 THE ROLE OF PET F-FDOPA IN THE EVALUATION OF GLIOMAS

Por Pace, A., Villani, V., Vidiri, A., Chiaravalloti, A., Floris, R., Schillaci, O., Fabi, A., Terrenato, I., Piludu, F., Carapella, C.M.
Publicado em 2014

P17.31 LONG-TERM SURVIVAL OF GLIOBLASTOMA PATIENTS: WHICH CLINICAL AND MOLECULAR CORRELATION?

Por Fabi, A., Villani, V., Pace, A., Antonello, V., Maschio, M., Carapella, C.M., Carosi, M.A., Cognetti, F., Marucci, L., Terrenato, I.
Publicado em 2014

Is stool DNA multitarget testing an unreliable strategy for colorectal cancer screening?

Por Ferretti, G, Bria, E, Carlini, P, Felici, A, Giannarelli, D, Cuppone, F, Papaldo, P, Nisticò, C, Fabi, A, Gelibter, A, Terzoli, E, Cognetti, F
Publicado em 2005

In situ protein expression of RRM1, ERCC1 and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy

Por Metro, G., Zheng, Z., Fabi, A., Schell, M., Antoniani, B., Mottolese, M., Monteiro, A.N., Vici, P., Rivera, S. Lara, Boulware, D., Cognetti, F., Bepler, G.
Publicado em 2010

Activity and Safety of Bevacizumab Plus Fotemustine for Recurrent Malignant Gliomas

Por Vaccaro, V., Fabi, A., Vidiri, A., Giannarelli, D., Metro, G., Telera, S., Vari, S., Piludu, F., Carosi, M. A., Villani, V., Cognetti, F., Pompili, A., Marucci, L., Carapella, C. M., Pace, A.
Publicado em 2014

Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?

Por Cazzaniga ME, Biganzoli L, Cortesi L, De Placido S, Donadio M, Fabi A, Ferro A, Generali D, Lorusso V, Milani A, Montagna E, Munzone E, Orlando L, Pizzuti L, Simoncini E, Zamagni C, Pappagallo GL
Publicado em 2019-04-01

Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials

Por Ferretti, G, Bria, E, Giannarelli, D, Felici, A, Papaldo, P, Fabi, A, Di Cosimo, S, Ruggeri, E M, Milella, M, Ciccarese, M, Cecere, F L, Gelibter, A, Nuzzo, C, Cognetti, F, Terzoli, E, Carlini, P
Publicado em 2006

Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study

Por Campiglio, M., Bufalino, R., Sasso, M., Ferri, E., Casalini, P., Adamo, V., Fabi, A., Aiello, R., Riccardi, F., Valle, E., Scotti, V., Tabaro, G., Giuffrida, D., Tarenzi, E., Bologna, A., Mustacchi, G., Bianchi, F., Balsari, A., Ménard, S., Tagliabue, E.
Publicado em 2013

Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer

Por Minuti, G, Cappuzzo, F, Duchnowska, R, Jassem, J, Fabi, A, O’Brien, T, Mendoza, A D, Landi, L, Biernat, W, Czartoryska-Arłukowicz, B, Jankowski, T, Zuziak, D, Zok, J, Szostakiewicz, B, Foszczyńska-Kłoda, M, Tempińska-Szałach, A, Rossi, E, Varella-Garcia, M
Publicado em 2012